Congress of Clinical Rheumatology (CCR) West, 2023
FILTER
Bimekizumab Efficacy and Safety in Biologic DMARD-Naïve Patients with Psoriatic Arthritis was Consistent With or Without Methotrexate: 52-Week Results from the Phase 3 Active Reference Study BE OPTIMAL
Bimekizumab Reduced MRI Inflammatory Lesions in Patients with Axial Spondyloarthritis: Week 52 Results from the BE MOBILE 1 and 2 Phase 3 Studies
Rheumatology Care Journey Among Patients with Psoriatic Arthritis or Axial Spondyloarthritis in the United States